BioNTech Commences Exchange Offer for CureVac Shares

BioNTech SE announced the commencement of a public exchange offer for all outstanding shares of CureVac N.V. The offer, made pursuant to a previously announced purchase agreement, aims to strengthen BioNTech's capabilities in mRNA-based cancer immunotherapy. Each CureVac share will be exchanged for approximately $5.46 in BioNTech American Depositary Shares (ADSs), subject to a collar mechanism. The offer will expire on December 3, 2025, unless extended or terminated earlier. The transaction is expected to create long-term value for shareholders of both companies and marks a milestone in BioNTech's oncology strategy.